Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

May 4, 2023

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 52 min

Earnings Call Speaker Segments

Larry Keusch

executive
#1

Good morning, everyone, and thank you for dialing in to Teleflex Incorporated's First Quarter 2023 Earnings Conference Call. Our press release, along with the accompanying slides for this call, is available on our website, teleflex.com. For those of you joining through the webcast, please note that you can advance the presentation slides on your own, so feel free to follow along at your own pace as we proceed. I'd also like to remind you that a replay will be made available on our website; anyone interested in listening can locate the necessary information in the press release we issued earlier today. Joining us on this call are Liam Kelly, our Chairman, President and Chief Executive Officer, and Thomas Powell, our Executive Vice President and Chief Financial Officer. Liam and Tom are going to deliver their prepared comments, and following that, we'll take questions from participants. Ahead of beginning, let me note that some topics covered during this conference call will contain forward-looking statements regarding upcoming events, as outlined in the slides available in the Investor Relations area of the Teleflex website; we'd like to warn you that these statements are indeed forward-looking and carry risks and uncertainties, so actual events or outcomes could differ materially. Things that might make real outcomes or occurrences come out significantly different cover, though aren't restricted to, the items mentioned in the release we put out today, plus the documents we submit to the SEC, such as our Form 10-K, which you're able to reach through our site; at this point I'll hand things over to Liam so he can share what he has to say.

Liam Kelly

executive
#2

Thank you, Larry, and good morning to all of you. It's great to be here with you today. Teleflex posted revenues of $710.9 million for the first quarter, which marked a 10.8% rise compared to the prior year on a reported basis, and 13.2% growth in constant currency terms. Adjusted earnings per share for Q1 came in at $3.09, up 7.3% from a year earlier; momentum from the close of last year carried into the first quarter, giving us a strong beginning to 2023. Even after backing out the effect of 5 additional shipping days during Q1, our underlying growth remained solid at 7.1%. As a reminder to investors, one day generally equates to roughly 1% of revenue growth in a quarter. During the first quarter of 2023, every extra day actually delivered slightly more than 1% growth. Taken together, those 5 additional shipping days contributed roughly 6% to our constant currency growth; within the quarter, both the high-growth portfolio, excluding UroLift, and the durable core achieved low double-digit year-over-year growth, once the 5 extra shipping days in the quarter are excluded. With the procedure environment improving, we performed well during the quarter, with every global product category contributing to growth. This balanced performance in the quarter once again highlights the advantage of Teleflex's diversified product portfolio and wide geographic footprint. During the quarter, we benefited from strong contributions in our interventional surgical and OEM product categories. Geographically speaking, Europe matched expectations, while Asia continues to be a key growth driver. On the macro front, inflation and supply chain conditions are stabilizing as we anticipated. Notably, we observed some easing and supply constraints for Tyvek during Q1 and still expect things to get better in the back half of the year as more industry capacity becomes available. We're also witnessing ongoing improvement when it comes to staffing challenges in the hospital setting. That showed up in our first quarter revenue growth, since most Teleflex products are tied to the hospital setting. On the other hand, we still see geographic pockets dealing with more persistent staffing disruptions in the ASC and office site of service; now let's take a deeper look into our first quarter revenue results. I'll start by reviewing our geographic segment revenues for Q1. All growth rates I mention are on a constant currency basis unless stated otherwise. Americas revenues reached $411.9 million, representing 9.2% growth year-over-year. We achieved growth across most of our businesses, including double-digit gains in interventional and surgical revenues; on top of that, the results reflected the impact of the 5 extra shipping days. EMEA revenues of $143.3 million rose 10.5% year-over-year. That year-over-year growth includes the benefit of the 5 extra shipping days in the quarter, while the underlying performance mirrors continued improvement in year-over-year procedure volumes that drove broad-based revenue growth across our product portfolio. Now turning to Asia. Revenues were $78.7 million, climbing 22.8% year-over-year. During the first quarter, we observed robust performance everywhere, with every geography delivering healthy growth. China continued to be a dependable driver, achieving very high single-digit expansion in the quarter. Surgical procedure volumes in China have still not come back to typical levels after the zero-COVID policy ended in late 2022, yet we did notice gains as the quarter went on. Going forward, we anticipate that China's growth will pick up speed over the rest of 2023. Now let's turn to our first quarter revenues by global product category. Discussion of global product category growth for Q1 will likewise be presented on a constant currency basis. Beginning with Vascular Access. Revenue rose 9.2% to $177.7 million. Results were strong throughout the portfolio, and we have now moved beyond the difficult COVID comparisons from 2022. As I mentioned earlier on this call, we experienced some easing in Tyvek supply during the first quarter and anticipate additional availability in the second half of the year as more manufacturing capacity for the industry becomes operational. Notably, our PICC portfolio went back to double-digit growth in the quarter. Over the long term, we stay positioned for reliable growth thanks to category leadership in central venous catheters and midline, expected share gains from our novel coated PICC portfolio and new product launches. Shifting to Interventional Access. Revenue reached $116.9 million, rising 23.3% year-over-year; we keep benefiting from our diversified portfolio and observed strength across our biggest product categories, such as complex catheters, balloon pumps and OnControl. MANTA keeps penetrating the sizable foreclosure market around the world. Now to Anesthesia. Revenue came in at $93.3 million, up 9.9% year-over-year. Among our larger franchises, hemostatic products, regional anesthesia and endotracheal tubes all delivered strong results in the first quarter, partially offset by LMA single-use masks; in our Surgical business, revenue totaled $99 million, up 14.3% year-over-year. Within our biggest product categories, metal ligation clips and instrument revenue grew double digits year-over-year. During the quarter, we moved forward with integrating Standard Bariatrics and trained new surgeons on using the Titan SGS Stapler in sleeve gastrectomy procedures. We featured Titan at the recent Sages Medical Conference, and feedback from surgeons was extremely positive. For Interventional Urology, revenue was $75.4 million, an increase of 0.9% year-over-year. We saw growth for UroLift in the hospital setting, but the apposite of service remains affected by staffing shortages. We still expect the U.S. end market for UroLift to keep improving as we move through 2023. Launch activities overseas in Japan and China are advancing as anticipated. OEM revenues climbed 34.5% year-over-year to $77 million. Strength in the quarter was widespread across our portfolio, with double-digit growth in every product category. We maintain good visibility into the business and see solid demand dynamics throughout 2023. Other revenue for the first quarter grew 6.4% to $71.6 million year-over-year. Our expectation remains that every bit of MSA revenue will come to a halt once 2023 ends, which means 2024 will see zero MSA revenue. With that, I've finished discussing how revenue performed in the first quarter. Now onto a few commercial and clinical developments. Our commercial strategy for the Titan SGS powered stapling device — used in sleeve gastrectomy procedures to treat obesity — keeps moving forward. Not long ago, we shared news of a supply agreement with W. L. Gore & Associates covering the use of that company's GORE SEAMGUARD Bioabsorbable Staple line reinforcement materials in a staple line reinforcement device that Teleflex designed for use alongside the Titan SGS stapler. Surgeons frequently rely on buttress material to cut down on leaks and bleeding and to make the staple line stronger by spreading the pressure from any single staple across a larger area, which also gives friable tissue added support. Being able to provide synthetic buttressing materials together with what makes the Titan stapler unique ought to let Teleflex better serve surgeon clinical needs and preferences within the sleeve gastrectomy market. We expect to bring the Teleflex applicator paired with Gore buttress materials to market by the close of 2023. Switching over to our hemostatic product portfolio: we've secured FDA 510(k) clearance for QuikClot Control+ for minor to moderate bleeding in cardiac procedures and bone bleeding following sternotomy.

Liam Kelly

executive
#3

This additional approved use builds on the earlier clearance covering short-term management of bleeding within internal organ spaces among patients who present with significant hemorrhage. This broader labeling came about after an IDE trial was finished and its data reviewed; that trial looked at how often subjects reached hemostasis within 10 minutes of applying the hemostatic agent and compressing the bleeding site. Findings from that trial showed the QuikClot Control+ hemostatic device performed better at attaining clinical hemostasis during cardiac surgery involving mild and moderate bleeding. With these expanded indications, QuikClot Control+ can now be used across a larger group of patients and a wider variety of surgical procedures, which grows the worldwide market potential for our hemostatic product portfolio. Promotion of the new indication kicks off next month; shifting now to news on the Interventional Access business; we feel good about the momentum we are building for 2023, centered on complex PCI and structural heart. Notably, our innovation engine remains a key priority, and a range of new products will roll out over the years ahead. To strengthen our channel position in complex PCI, we recently started a limited market release of the GuideLiner Coast, and physicians who have used it so far have given positive feedback. The GuideLiner Coast extends our successful GuideLiner extension catheter franchise by adding a hydrophilic coating that boosts deliverability. Beyond that, a limited launch of the Triumph micro-catheter is set to begin in the second quarter. Triumph offers a distinctive catheter design and will be backed by a chronic total occlusion clinical study that is expected to begin enrolling patients in 2023; meanwhile, our Ringer perfusion balloon catheter keeps moving forward, with 2 clinical studies now enrolling patients. On a separate note, our structural heart footprint keeps growing. MANTA and the Langston dual lumen catheter are being sold today by our dedicated salesforce. Going forward, we are working actively to broaden our product lineup with the Watson, which stands as the next product we expect to launch. The Waston is a distinctive dual delivery guidewire and pacing wire intended for TAVR procedures. Finally, here is an update on our Vascular Access business. We are pleased to share that 2 new devices have been launched, both aimed at improving PICC insertion procedures and lowering the risk of complications. To start, we have launched the next-generation Arrow VPS Rhythm DLX device, which delivers real-time information on PICC catheter tip location by using the patient's cardiac electrical activity. This device also includes an optional integrated ultrasound module that helps with vascular access, and when paired with our tip tracker technology, use of the DLX removes the need for confirmatory x-ray, cutting time to therapy and cost. We have also launched a new Arrow PICC preloaded with the NaviCurve Stylet. The NaviCurve Stylet has an anatomical curb and a flexible tip, both engineered to self orientate to the patient's anatomy so PICC advancement into the superior vena cava is enhanced for successful insertion. That wraps up my prepared remarks. At this point, I'd like to hand things over to Tom, who will walk us through the first quarter's financial results in greater detail. Tom?

Tom Powell

executive
#4

Thank you, Liam, and good morning. Since we already covered how the company performed on revenue, I'll start with margins. Adjusted gross margin for the quarter came in at 59.4%, which represents a 100 basis point gain over the same period a year ago. That year-over-year improvement was driven mainly by price, reduced costs tied to logistics and distribution, and favorable movements in foreign currency exchange rates, though it was partly offset by ongoing cost inflation, including raw materials and labor. Notably, in the first quarter we held firm on our pricing discipline, and we still anticipate no less than 50 basis points of positive price on a year-over-year basis during 2023. In the first quarter, adjusted operating margin reached 25.8%. The 10 basis point year-over-year rise came about through flow-through of the gross margin, partly offset by headcount and employee-related expenses, investments aimed at growing the business, and the inclusion of standard bariatrics. Net interest expense came to $17.5 million in the first quarter, up from $10.2 million in the same period last year. That year-over-year rise in net interest expense is a reflection of higher interest rates relative to the prior year, partly offset by a decrease in average debt outstanding. Our adjusted tax rate for the first quarter of 2023 stood at 11.8%, versus 11.9% in the prior year period. On the bottom line, adjusted earnings per share for the first quarter was $3.09, which is a 7.3% increase over the prior year. Now I'll turn to a few balance sheet and cash flow highlights. Cash flow from operations in the first quarter was $84.3 million, compared with $62.1 million in the prior year period. That gain was driven mainly by favorable working capital changes resulting from higher accounts receivable collections, partly offset by a rise in inventories to sustain high customer service levels amid a stretch of elevated global supply chain volatility. Moving on to the balance sheet. Our financial position keeps giving us the flexibility to run the business and to carry out our disciplined capital allocation strategy. At the close of the first quarter, our cash balance was $264.1 million, versus $292 million as of year-end 2022. The decrease in cash on hand stems primarily from $75 million of payments on our senior credit facility. Net leverage at the end of the quarter was roughly 1.7x, which is still comfortably under our 4.5x covenant. Now I'll move to financial guidance. We're quite pleased with how we performed financially in the first quarter. Notably, we've observed a recovery in surgical procedures, especially those done in the hospital, staffing shortages in the hospital continue to ease, and inflation along with supply chain headwinds have settled down. With such a solid start to the year, we're updating our 2023 financial guidance. More specifically, we're lifting the low end of our 2023 constant currency revenue and now expect growth of 5% to 6.25%. Shifting to foreign exchange. We now assume a foreign exchange translation headwind of roughly 35 basis points in 2023. Earlier, when we gave guidance, we projected a 50 basis point headwind for 2023, and that was based on a $14 million adverse foreign exchange effect across the entire year, with $17 million of that anticipated during the first quarter. What actually happened in the first quarter was a headwind roughly $4 million smaller than we had anticipated. Our updated foreign exchange guidance for 2023 reflects the rates that actually occurred in the first quarter, while the foreign exchange assumptions we established at the start of 2023 stay the same for the rest of the year. Taking into account this revised foreign exchange headwind, our expectation is reported revenue growth between 4.65% and 5.9% for 2023, which translates to a dollar range of $2.921 billion to $2.956 billion; for 2023, we are reaffirming our guidance on adjusted earnings per share of $13 to $13.60. We are reducing our GAAP adjusted earnings per share outlook to $8.14 to $8.74, mainly because of a onetime tax item. Every other component of our adjusted financial guidance for 2023 stays as it was, including our outlook for adjusted gross and operating margins. That wraps up my prepared remarks. Now I'd like to hand it back to Liam for closing commentary.

Liam Kelly

executive
#5

Thanks, Tom. To wrap up, I want to point out 3 main points from Q1 of 2023. To begin, 2023 got off to a solid start since the momentum we saw at the close of last year carried over. Our worldwide operations were run well, and we kept handling the macro headwind effectively. Next, that strong Q1 showing leaves us in a good spot to meet our financial guidance for 2023. The atmosphere around health care utilization looks more and more steady. Because of that, we anticipate that our high-growth portfolio will perform better as 2023 goes on, along with ongoing strength in our durable core. Third, and this matters a lot, our attention will stay on the strategy meant to produce durable growth. We'll put money into organic growth possibilities and push innovation, widen our margins, and carry out our disciplined approach to capital allocation so that long-term value creation is strengthened. That's all I had for my prepared remarks; at this point I'd like to hand the call back to the operator for Q&A.

Cecilia Furlong

analyst
#6

Liam, to begin, I'd like to hear some of your thoughts on what recovery looks like from where you sit — in hospitals, in ASCs, and in office-based environments. But when it comes to UroLift specifically, could you describe what you're observing, and where things stand on the recovery front in the hospital setting compared with ASC and office-based settings? Then, how do you view the remainder of the year against that longer-term CAGR of 8% to 9% for the business? Looking at where you are right now, how do you see it tracking against that growth rate?

Liam Kelly

executive
#7

Thanks for the question, Cecilia. Let me begin at the macro level, looking at procedures overall. Clearly, the 13.2% growth we delivered in Q1 came in ahead of what we expected. Excluding the days that landed above 7%, our first quarter was one we're really pleased with, given that our guidance at the midpoint was roughly 6%. Procedure volume in hospitals overall has kept advancing and making progress. We're seeing that especially in the Americas and in EMEA. And in APAC, what we observe overseas is a strong environment. And we see, particularly once you got through March, that China began to pick up. On UroLift specifically, growth on the hospital side of service came through once again, which is encouraging. That now makes it sequential quarters of growth on the hospital side of service. On the office side of service, there was some modest improvement, but it remains challenging because of staffing issues and, obviously, because of patient flow. And anyone who follows Teleflex will recognize that the patient flow dynamic really began having an impact once you moved into the latter half of the year. It started as you went through Q2 into Q3. So as we move through the year, we would still expect an improving environment for UroLift. During the quarter, UroLift performed as expected in the first quarter of this year, and we feel good momentum is building. Our presence at AUA was really strong, and the enthusiasm we see from urologists encourages us.

Shagun Singh Chadha

analyst
#8

Your 2023 revenue guidance, then, suggests growth will step down across the rest of the year. What's behind that view? Is conservatism a factor, or is there something else worth flagging? And what should we expect for the cadence over the remainder of the year? Turning to EPS, you kept the EPS figure even after the Q1 beat. I'm curious whether there are P&L offsets at play that explain why the EPS range wasn't narrowed?

Liam Kelly

executive
#9

All right. In a moment I'll have Tom address the EPS piece. On the revenue side, Shagun, I'll take that one. During the first quarter we made it very clear that our plan is front-end loaded. And from an investor's standpoint, I'd prefer a company with a front-end loaded plan over one that's back-end loaded. A few dynamics come into play in certain areas of our businesses. Naturally, as the year progresses, we run into some tougher comparables once you reach the back half of the year. Naturally, this reflects a day's impact. The first quarter carries 5 additional days. Quarter 4 carries 5 fewer days; even so, we feel really good about the full year. A strong start boosts our confidence in our capacity to hit our guidance as the year unfolds; and beyond that, it's one quarter. It's the year's first quarter. A good solid start is great to have. We'd like another couple of quarters behind us, and then we'll see where we land; but we do sense there's greater momentum behind Teleflex and our momentum in the marketplace, purely based on the procedural dynamic and on some of our key business units and regions performing exceptionally well. Units such as OEM, Interventional Access posted really strong margins in the month of March. It's really good to see Vascular return to growth as expected. We told investors Vascular would return to growth. It's great to see that return to growth happening. The high-growth portfolio posted a really solid first quarter. And durable core, as expected, outperformed in the first quarter, purely because of that whole procedural volume. I'll have Tom briefly discuss the other part of your question, around EPS.

Tom Powell

executive
#10

All right. Regarding earnings per share, one thing to remember is that we hadn't given any quarterly EPS guidance for Q1 to begin with. When the quarter closed, our EPS figure landed right where we had expected internally. That keeps us quite confident about the full-year EPS guidance outlook, and we're really happy with the way Q1 finished. So, as Liam said, keep watching — we'll keep an eye on things. Still, I feel really, really good about how the quarter went.

Kristopher Campbell

analyst
#11

Matt Taylor isn't here — this is Chris filling in for him. You mentioned UroLift's growth briefly. Could you go into more detail about the high-growth portfolio and the trends you're observing in it, and also touch on the Standard Bariatrics acquisition?

Liam Kelly

executive
#12

Sure, happy to. Chris, I appreciate that question. What I'd say is Titan got off to a very strong beginning this year. Our expectation remains $30 million to $35 million. MANTA launched and is right where we want it for the entire year. Hemostats performed extremely well during Q1. It got off to a fast start, cleared an intraosseous, and landed in line. And PICCs — it's wonderful to see them growing again. We'd told investors that as soon as the Tyvek issue began improving, growth in PICCs should resume, and that is precisely what occurred in the quarter. PICCs delivered a very solid result, and we'd look for that to keep going throughout the year. My anticipation is that a lot of the components of the high-growth portfolio will keep speeding up over the course of the year. That applies to UroLift, MANTA, Titan, the PICCs, plus a portion of the intraosseous portfolio; that's our expectation, and it's what our guide accounts for.

Mike Matson

analyst
#13

I wanted to ask about UroLift specifically. Did you experience the same level of selling day impact there as you did across the rest of the business? Because if so, that would suggest to me a fairly significant decline there as well, somewhere around mid-single digits, I believe. Or is there some reason UroLift didn't get that benefit?

Liam Kelly

executive
#14

Yes. So Mike, UroLift's days impact mirrors what we're seeing in the rest of the business. So that would — you're exactly right, that would indicate a modest decline. But Mike, that's precisely what we anticipated for the first quarter, and it played out just as we had expected. We did obtain some analysis regarding the days impact. We have it through January and February — excuse me, on the patient flow impact, and we have that through January and February; and across the first 2 months of the quarter, patient flow went down by another 3.7%. As we move through the year, Mike, what we expect to see is getting past the difficult comparable on patient flow. As I mentioned a bit earlier, the patient flow dynamic truly began to worsen noticeably in 2022 as the year progressed, starting in Q2 and Q3, when we saw double-digit declines in patient flow. Once we get beyond that comparable, we would expect, as we progress through the year, an improving environment for UroLift.

Mike Matson

analyst
#15

All right, that makes sense. And regarding that MSA headwind — could you put a figure on it once more, just so we remember and can work it into our models the right way?

Liam Kelly

executive
#16

Sure. As we move from '23 to '24, the MSA headwind comes to roughly $70 million, Mike. So — however, that revenue carries low margins, and it's disappearing. You're losing that $70 million in revenue. Yet further down the income statement, gross margin should improve by about 100 basis points because that MSA is no longer there. And naturally, that was exactly the point behind Teleflex pruning so it could grow — the respiratory assets were assets with lower growth and lower margins. Investors will now reap the reward in 2024, since that entire low-growth segment has left our portfolio, the MSA has left our portfolio, and you'll notice an effect on gross margins, with a portion of that flowing through to op margins in '24 too.

Jayson Bedford

analyst
#17

A few things I'd like to ask. OEM and Interventional both did really well, with growth that beat expectations. I just want to confirm nothing unusual, no one-time items, is behind that. Then second, regarding OEM, you said visibility looks solid all the way through '23. What rate of expansion do you expect out of that segment?

Liam Kelly

executive
#18

Well, OEM got off to a fantastic start, 34.5%. Clearly, you need to strip out part of that — the effect of the days. It happened everywhere; catheters were a real strength; extrusion was a real strength too. Sutures turned in a great result. That company we bought a couple of years back, HPC, keeps delivering outstanding results and lets us move some of our offerings through to other buyers. We'd still anticipate OEM growing in the high single, low double-digit territory, though probably tilting toward the low double digits now, because the year began so strongly. March was a really good month for them, landing a touch above what we'd forecast; plus they enjoyed an easier comparison against the prior year in Q1, which gave them a lift. Still, the momentum they brought with them out of Q4 rolled on into Q1 and they're doing outstandingly well; and honestly, OEM has done outstandingly well across the last 3 years. This isn't merely a single-quarter fluke, despite the fact that this quarter came in slightly stronger. Turning to Interventional Access, once more, an extremely robust result, with growth above 23%. Langston being back on the market truly matters — complex catheters, the GuideLiner, TrapLiner, Turnpike all did well. A great deal of procedural volume carries us through that. Later in the year, they — during Q3, they'll be up against the comp from Langston's reentry into the market. Even so, this will be a pleasant, dependable growth engine, with genuinely good margins; and as we laid out in our prepared remarks, a genuinely attractive setup as new offerings arrive, with the GuideLiner Cost, with the Watson, with the Ringer and with the Triumph now reaching the market. So new products have traditionally been what keeps this business alive; and we — certain adjustments we implemented in how we run R&D have genuinely begun to pay off, as you picked up from what I said in my prepared comments; so OEM and IA, you're correct, Jayson, are the pieces that essentially fueled the beat versus the 6% to 7% we'd expected in Q1.

Larry Keusch

executive
#19

Larry, on the OEM side — sorry, thanks for the question.

Liam Kelly

executive
#20

That business is among those where our forward view stretches furthest. So for that unit, I expect conditions to stay quite steady across the coming stretch of time.

Anthony Petrone

analyst
#21

Perhaps Liam or Tom could offer some big-picture thoughts regarding procedure volumes. In Vascular and Interventional, we definitely observed plenty of data points during the quarter showing that we have reached a new level when it comes to procedure volumes specifically. It's not that staffing problems have gotten back to normal, but rather that hospital workflow has gotten better; so perhaps just a bit about how sustainable procedure volumes are in general across the other hospital businesses, not specifically outpatient; and after that I'll ask a follow-up too.

Liam Kelly

executive
#22

Sure, Anthony, I mean, clearly, during the quarter, with growth of 7% after a Q4 of 4.3% and an adjusted full year last year of 4.3%, the improvement is visible. I mean it involves more than just procedural volumes. Many of the new products we're discussing are gaining momentum inside the business. Clearly, having standard bariatrics and the Titan product is a help to us. But I've said this for many quarters now. If you've been in the hospital recently and I believe it will certainly hold up across a number of quarters, procedural volume is really strong. There's a great deal of drive to get procedures completed. We're seeing that widely in EMEA and in the Americas. And as I mentioned a little earlier, with China returning on stream, we would expect to get extra growth from procedure volume coming through from that lockdown practice within APAC and particularly within China. As for staffing, it isn't back to where it was; that would be my observation, but it keeps getting better and better and better each quarter. And I think regarding your comment about the other sites of service, once things improve in the hospital, we will see that carry through to the ASC and the office in the near term. And I think what we're seeing on the hospital side of the service is very encouraging. So I view it as pretty sustainable across a multi-quarter period, Anthony, but I wouldn't want you to leave thinking it's just procedural volume. There are certain things we're doing uniquely within Teleflex that are driving a lot of our momentum as well.

Anthony Petrone

analyst
#23

That sounds excellent. As a follow-up, could you share your latest perspective on the M&A landscape? We're noticing deals getting done in this sector. Perhaps an update on how you're viewing valuations? And also the expense of financing. I mean, with where the debt markets stand right now, how does that shift the calculation when Teleflex evaluates M&A?

Liam Kelly

executive
#24

Absolutely, Anthony. We're quite active in the market. Our leverage stands at 1.7x at present. That gives us the single most critical ingredient for pursuing M&A — we've got firepower. At this moment, we'd possess the capability — and I'm not suggesting this is something we will pursue — but we'd possess the capability to deploy roughly $2 billion in capital. We remain extremely engaged across every segment of M&A. We're genuinely pleased about bringing Standard Bariatrics on board; and I believe we're evaluating tuck-ins. We're evaluating scale; we're evaluating late-stage technologies in every category. I'll touch on the expense of financing, though perhaps I'll invite Tom to weigh in too. What I believe we're observing is that the expense of financing is getting somewhat better. So we consider the climate slightly improved compared to even several months back. As for valuations, my sense is they're at the same level as they've been across recent quarters. They've retreated from the overheated period midway through 2021. And I'd describe it as a climate that's highly appealing for Teleflex; but Anthony, we'll stay disciplined. Investors ought to understand that whenever we announce a transaction and integrate something into Teleflex, we've completed the necessary diligence and it's the correct transaction for Teleflex. Tom, is there anything you'd like to contribute regarding the expense of financing?

Tom Powell

executive
#25

Okay, what I was about to add is this — sure, funding costs have risen compared with a couple of years back, or even just 12 months ago, but on the whole they remain at pretty sensible levels when you weigh where we see the cost of funds today against where it has sat across the last 10 or 20 years. So at this moment, I don't think that's going to hold us back from being able to find assets. At present, then, our attention is genuinely on locating the strategic fit that works for us, and the cost of funds will definitely play a part — just not a constraining one.

Craig Bijou

analyst
#26

I'd like to talk about margin for a moment. You've clearly lifted the revenue outlook, yet the margin outlook stayed where it was. So could you take us through how gross margin and operating margin are expected to play out across the year? And since Q1 came in better on both gross margin and operating margin than the same period a year earlier, which puts us ahead of where your full-year guidance for '23 sits, why wouldn't there potentially be some upside to the margin guidance? And what factors ought we to keep in mind regarding margins for the remainder of the year?

Liam Kelly

executive
#27

Yes, Craig, thanks for asking. One thing I'd like to highlight is that it's May, so we're still very early in the year. We're extremely pleased with how we started the year, on revenue, on margins and on earnings. A good start is half the battle, as my late mother, God rest her, used to say, and our start has been a good one. That said, I'll hand it to Tom to give you a bit more color on some of the margin impacts, if that's all right, Tom.

Tom Powell

executive
#28

Alright, regarding gross margin, what you should anticipate is that it stays fairly steady for the rest of this year. There will be some fluctuation, though it won't be far from the current level. Turning to operating margin, expect that metric to improve on a sequential basis as the year progresses. A few points worth remembering: when you compare gross margin against the prior year, the first quarter gave us a more favorable comparison than what we'll see for the remaining portion of the year, so that factor definitely matters when reviewing year-over-year figures. On top of that, we anticipate foreign exchange pressures affecting gross margin over the course of the year. During Q1, we enjoyed a solid gain, but as you may remember, the dollar shifted considerably starting in Q2 and Q3 of last year, which means the comparison ahead becomes tougher. Those are among the elements I consider. Still, to repeat, gross margin remains fairly consistent across the year, while operating margin is set to deliver sequential gains.

George Sellers

analyst
#29

Congratulations on the quarter. Perhaps a somewhat smaller question regarding the Titan stapler. I realize it remains a fairly modest portion of the business; however, when it comes to the Gore buttress material, what implications does that carry for the gross margin on that device? And regarding producing it, is there a chance that eventually you could move that manufacturing in-house?

Liam Kelly

executive
#30

Yes, George, many thanks. So to begin with, I would say we're extremely happy with how Titan performed during the first quarter. It generated a great deal of the favorable momentum in the surgical business, and our surgical business turned in a really, really strong showing. Consequently, arriving at 14% growth, the buttress material won't affect the margin expectations for this business at all. We continue to anticipate that this business, as we move through '24, will become accretive to Teleflex's gross margin and then truly leverage after that. What we expect is to keep this parity or keep having this product made by — in the — the way we currently do, and we have no intention of making any adjustments to that at this point. Clearly, it's scaling quite quickly. We don't wish to disrupt it; and the third party we're collaborating with is extraordinarily dependable and genuinely doing a strong job; so may that last a long time, and we'll keep scaling this product throughout this year, and we still anticipate it will deliver $30 million to $35 million in revenue this year. And that volume will assist us, obviously, in leveraging the gross margin as we head into '24, George; and thank you for the question.

Mike Polark

analyst
#31

Perhaps a follow-up about Standard Bariatrics; and if you already mentioned it, I didn't catch it. Could you put a number on how much revenue it brought in during the quarter? I'm aware of what the 2023 full-year outlook looks like. But I'd just like to get a sense of where 1Q began so we can better gauge the ramp across the remaining months?

Liam Kelly

executive
#32

Sure, Mike, we don't provide a specific revenue breakdown for it. Clearly, we feel good about the $30 million to $35 million for the product. And I'll say, as I mentioned a bit before, this is a product that's going to keep ramping as the year progresses; but once again, quarter 1 got off to a really strong start. So that strengthens our confidence in the $30 million to $35 million for the full year, and the product is doing extremely well; we actually displayed it at Sages, and we received a lot of really, really favorable responses regarding the product at Sages; it's solving many of the unmet needs that bariatric surgeons have. And the buttress we're adding to it addresses one of those obstacles. Some surgeons simply prefer to use buttress when sealing; and with the Titan it's probably less necessary than it is with competing technologies. But if that's the approach they wish to take, then we'll back them in doing so. So I believe all of that points in a positive direction for the Titan across a multiyear stretch.

Mike Polark

analyst
#33

Let me ask one more thing, and this time about Tyvek. From what I recall, I believed the industry might see some relief during the latter six months of the year. It sounds as though things are getting better right now. So what's behind that? Is it simply that additional supply is arriving, and how — was it sort of — what has the pattern looked like? And have you returned to normal there, or are you very nearly there? Is there any sort of framework for where things stand? Then, on a related note, could you remind us which revenue lines within the segments have taken the biggest hit from that situation, and therefore where the comps are — which comps are the simplest as — as supply gets better.

Liam Kelly

executive
#34

Yes. I'll borrow your phrase. We are very nearly back to normal; we're not fully back to normal yet, Mike, though the movement is in a positive direction. And it's better than what we had expected during Q1. You're right. When we reach the second half of the year, the Tyvek provider brings new supply online, and that will put the issue to rest. The 2 lines affected — the 2 is essentially within our Vascular business. To a smaller degree, it's our CVCs, since we gave priority to the supply on hand in order to hold our market share position in CVCs. What this has caused is that we've been unable to convert PICC accounts. As you heard during my prepared comments, it was good to see PICCs return to double-digit growth this quarter, because we can now go back out and begin converting those accounts. As a reminder to investors, our PICC portfolio stands out in that it carries both an antimicrobial and an anti-thrombogenic coating. That's the reason we're seeing wide adoption for this portfolio around the world and especially in the United States, where we aren't the market leader, we see a strong chance to keep gaining share.

Richard Newitter

analyst
#35

I've just got one question. Regarding UroLift, I suppose, those remarks about patient flow still experiencing some delay. I suppose even certain other med tech subcategories that got better yet remain lagging, such as elective procedures—knees and hips, for instance—even those seemingly had some patients returning to the channel for physician appointments and that kind of thing. I'm simply wondering, is there anything particular to UroLift that stands in contrast to a few of those other procedures—not UroLift, pardon me, but rather the doctor visit and patient flow? I'm just attempting to grasp why perhaps specific neurological procedures such as this would continue trailing to that degree relative to the remainder of the med tech landscape.

Liam Kelly

executive
#36

Well, Rich, a few points come to mind. To begin with, whenever you perform hips and knees, those aren't being done on urology patients. So this is something distinct to the urology field. There are a handful of factors regarding urologists. Within the United States, urologists' average age is 55; thus the demographic delivering care is getting older. And it's—we likely have greater exposure to the office portion of service than any of the hips and knees folks or any other—or even any of our counterparts in the urology call point. As investors acquainted with Teleflex will recognize, roughly 30% of our UroLift revenue comes from within the office. And I can tell you the information we possess indicates patient flow fell 3.7% across January and February; the bright side now, Rich, is that after we reach the year's latter half and move forward, the hardest comp on patient flow will be behind us as we advance through the year. So from that standpoint, we do expect a bettering environment. And the excitement for UroLift among urologists at AUA was nearly tangible. I was present in Chicago earlier this—in late April. And versus 12 months prior, attendance was far greater. It genuinely felt positive. It was buoyant. We held plenty of education seminars featuring lots of podium presence there. And I'd say at that conference, it was nearly a return to the good old days of UroLift. Thus we do expect a bit of a bounce from that, and we do expect the back half of the year to be stronger.

Larry Keusch

executive
#37

Thanks, Adam, and thanks to each of you who were on the call with us today. That brings the Teleflex Incorporated First Quarter 2023 Earnings Conference Call to a close.

Operator

operator
#38

That wraps up the session for today. We appreciate you all joining us. At this point, feel free to hang up.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.